A study of distribution of doripenem in otolaryngologic tissues and clinical relevance in otolaryngologic infection
|
Accession number;05A0663332
|
| Title;A study of distribution of doripenem in otolaryngologic tissues and clinical relevance in otolaryngologic infection |
| Author;
BABA SHUNKICHI
(Nagoya City Univ., Med. Sch.)
SUZUKI KENJI
(Fujita Health Univ., School of Medicine)
MIYAMOTO NAOYA
(Aichikenkoseinogyokyodokumiairengokai Kamobyoin Jibiinkoka)
|
Journal Title;Japanese Journal of Chemotherapy
|
Journal Code:F0608A
|
ISSN:1340-7007
|
|
VOL.53;NO.Supplement 1;PAGE.293-302(2005)
|
| Figure&Table&Reference;TBL.13, REF.14 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;We studied the distribution of doripenem (DRPM), a new carbapenem antibiotic for injection, in otolaryngologic tissue. To evaluate the efficacy and safety of DRPM, we also conducted an open-label clinical trial in patients with moderate to severe otitis media and peritonsillar abscess (including severe lacunar tonsillitis and peritonsillitis). After an infusion of DRPM (250 mg), the concentration in removed tissues (palatine tonsil and mucosa of middie ear), and the ratio to plasma concentration in the same period were 0.27-2.58 .MU.g/g and 6.1-33.2% (60-155 minutes) in the palatine tonsil and 0.26-6.09 .MU.g/g and 2.7-42.9% (60-90 minutes) in the mucosa of the middle ear. DRPM was administered at a dose of 250 mg b.i.d., 250 mg t.i.d., or 500 mg b.i.d. for seven days. In otitis media, DRPM was "highly effective" in four patients and "effective" and "slightly effective" in one each. In peritonsillar abscess, DRPM was "highly effective" in four patients and "effective" in two patients. After DRPM infusion at the clinically recommended dose of 250 mg, the concentration of DRPM in middle ear discharge and the ratio to plasma concentration in patients with otitis media were 0.32-0.72 .MU.g/mL and 4.2-18.8% (75-170 minutes). Microbiological response was studied in nine patients-five with otitis media and four with peritonsillar abscess. We found it to be "eradicated" in four patients and "decreased" in one with otitis media; while in peritonsilar abscess, it was found to be "eradicated" in all the four. In safety, the incidence of adverse drug reactions (abnormal symptoms) was 6.7% (1/15) and that of adverse drug reactions (abnormal laboratory findings) 26.7% (4/15), none of which were serious.... (author abst.) |
|
|
|
Related Articles;
|
|
